Uncategorized

Russia’s Biosimilar Powerhouse: BIOCAD’s Patent Pipeline and the Oncology Disruption No One in the West Is Watching

Russia’s biosimilar story is no longer a footnote—it’s a blueprint. And if you’re only watching Western launches and Western pipelines, you’re missing the quiet buildout that could reshape oncology access, pricing dynamics, and competitive strategy acr…

Russia’s Biosimilar Powerhouse: BIOCAD’s Patent Pipeline and the Oncology Disruption No One in the West Is Watching Read Post »

Uncategorized

Read the Drug Patent Clock Before the Market Does: A step-by-step technical guide to forecasting pharmaceutical drug patent expiry for IP teams, R&D strategists, and institutional investors

The drug patent clock is ticking—here’s how IP teams can forecast expiry before the market prices it in.
Most IP teams don’t lose because they miss the existence of a patent. They lose because they miss the timing.
In pharma, timing is everything: laun…

Read the Drug Patent Clock Before the Market Does: A step-by-step technical guide to forecasting pharmaceutical drug patent expiry for IP teams, R&D strategists, and institutional investors Read Post »

Uncategorized

Drug Market Entry Intelligence: The Definitive Guide for Pharma Strategists, IP Teams, and Institutional Investors

Pharma strategy is entering a new era—one where “knowing the market” is no longer enough.
In the past, drug market entry planning often meant stitching together fragmented signals: trial timelines, label expansions, competitor pipeline chatter, and a h…

Drug Market Entry Intelligence: The Definitive Guide for Pharma Strategists, IP Teams, and Institutional Investors Read Post »

Biotechblog
Scroll to Top